Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

BLUE | bluebird bio, Inc.

IndexRUT P/E- EPS (ttm)-1.03 Insider Own1.20% Shs Outstand108.69M Perf Week-7.91%
Market Cap328.03M Forward P/E- EPS next Y-1.66 Insider Trans-1.69% Shs Float106.04M Perf Month-11.10%
Income-96.00M PEG- EPS next Q-0.67 Inst Own81.30% Short Float / Ratio24.56% / 6.26 Perf Quarter-8.73%
Sales9.40M P/S34.90 EPS this Y58.50% Inst Trans14.27% Short Interest26.04M Perf Half Y-29.08%
Book/sh2.66 P/B1.16 EPS next Y15.30% ROA-15.80% Target Price7.10 Perf Year-50.00%
Cash/sh2.31 P/C1.34 EPS next 5Y45.80% ROE-38.40% 52W Range2.78 - 8.58 Perf YTD-55.42%
Dividend- P/FCF- EPS past 5Y19.70% ROI-146.30% 52W High-64.04% Beta0.92
Dividend %- Quick Ratio2.00 Sales past 5Y-36.70% Gross Margin-37.80% 52W Low10.97% ATR0.21
Employees323 Current Ratio2.10 Sales Q/Q360.00% Oper. Margin- RSI (14)35.57 Volatility4.92% 5.49%
OptionableYes Debt/Eq0.00 EPS Q/Q50.60% Profit Margin- Rel Volume0.50 Prev Close3.20
ShortableYes LT Debt/Eq0.00 EarningsAug 08 BMO Payout- Avg Volume4.16M Price3.09
Recom2.60 SMA20-12.91% SMA50-13.70% SMA200-33.46% Volume1,694,884 Change-3.59%
Date Action Analyst Rating Change Price Target Change
Sep-06-23Initiated HSBC Securities Buy $4.21
Jul-19-23Upgrade BofA Securities Neutral → Buy $6 → $10
Jun-01-23Upgrade Barclays Equal Weight → Overweight $7 → $8
Apr-28-23Initiated JP Morgan Overweight $7
Mar-07-23Initiated Robert W. Baird Outperform $10
Aug-05-22Upgrade Barclays Underweight → Equal Weight
Aug-02-22Upgrade Raymond James Mkt Perform → Outperform $8
Apr-06-22Downgrade Cowen Outperform → Market Perform
Mar-07-22Downgrade Barclays Equal Weight → Underweight $4
Nov-08-21Reiterated Wells Fargo Equal Weight $25 → $16
Sep-20-23 07:21AM
Sep-12-23 07:00AM
Sep-07-23 11:30AM
Sep-05-23 04:05PM
05:25AM Loading…
Aug-29-23 05:25AM
Aug-28-23 08:30AM
Aug-24-23 10:15AM
Aug-16-23 07:00AM
Aug-08-23 08:25AM
Aug-05-23 09:40AM
Jul-27-23 11:19AM
08:00AM Loading…
Jul-25-23 08:00AM
Jul-22-23 06:14AM
Jul-20-23 01:14AM
Jul-19-23 12:36PM
Jun-30-23 10:15AM
Jun-29-23 09:53AM
Jun-21-23 07:00AM
Jun-15-23 10:00AM
Jun-08-23 11:30AM
Jun-01-23 02:09AM
May-10-23 07:57AM
May-09-23 07:10AM
Apr-27-23 04:05PM
03:49PM Loading…
Apr-24-23 03:49PM
Apr-13-23 02:17PM
Apr-06-23 10:15AM
Apr-02-23 09:15AM
Mar-30-23 01:54PM
Mar-29-23 08:15AM
Feb-24-23 10:00AM
Feb-08-23 08:05AM
Feb-03-23 05:00AM
Jan-30-23 09:12AM
Jan-24-23 08:58AM
Jan-22-23 09:00AM
Jan-18-23 08:00PM
Jan-09-23 07:00AM
Jan-07-23 10:07AM
Jan-06-23 07:30AM
Jan-05-23 01:13PM
Jan-03-23 08:00AM
Dec-28-22 12:32PM
Dec-26-22 08:00AM
Dec-24-22 08:07AM
Dec-21-22 08:54AM
Dec-19-22 01:48PM
Dec-12-22 06:56PM
Dec-10-22 11:30AM
Dec-07-22 11:30AM
Dec-06-22 10:07AM
Nov-30-22 09:48AM
Nov-17-22 10:07AM
Nov-07-22 08:25AM
Nov-02-22 04:05PM
Oct-28-22 10:00AM
Oct-27-22 09:30AM
Oct-04-22 12:00PM
Oct-03-22 03:20PM
Sep-30-22 12:38PM
Sep-24-22 09:45AM
Sep-22-22 05:37AM
Sep-21-22 01:03PM
Sep-20-22 05:00PM
Sep-19-22 01:45PM
Sep-17-22 02:47PM
Sep-16-22 11:51PM
Sep-13-22 06:46AM
Sep-12-22 07:30AM
Sep-10-22 10:15AM
Sep-06-22 10:15AM
Aug-29-22 08:00AM
Aug-23-22 07:20AM
Aug-19-22 06:33PM
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Klima Thomas JSee RemarksSep 05Sale3.799223,493132,127Sep 06 04:30 PM
Obenshain AndrewPresident and CEOAug 10Sale3.5416,92959,956291,941Aug 10 05:00 PM
Klima Thomas JSee RemarksJun 02Sale3.504,13014,451133,049Jun 06 04:06 PM
Leschly NickDirectorJan 11Sale7.804,29033,480280,149Jan 13 04:19 PM
Obenshain AndrewPresident and CEOJan 11Sale7.803,17824,802242,690Jan 13 04:19 PM
Colvin Richard AChief Medical OfficerJan 11Sale7.805574,34774,231Jan 13 04:19 PM
Obenshain AndrewPresident and CEONov 04Sale6.411,2638,101245,868Nov 08 05:46 PM
Colvin Richard AChief Medical OfficerNov 04Sale6.412181,39874,788Nov 08 05:46 PM
Leiderman ElisabethDirectorOct 17Sale6.461,0046,49011,466Mar 09 04:06 PM